The convergence of 3D bioprinting, stem cell research, and tissue engineering is rapidly moving us toward a future where artificial organs are not only feasible but customizable and readily available. With global shortages of donor organs and rising demand for transplants, the ability to print living tissues—layer by layer, cell by cell—offers a revolutionary alternative. Scientists have already bioprinted functional skin, corneas, bone, and cartilage, and the race is on to replicate more complex structures like kidneys, livers, and even beating hearts. These artificial organs, created from a patient’s own cells, drastically reduce the risk of rejection and eliminate the dependency on donor systems plagued by long waiting lists and ethical issues. Beyond transplantation, bioprinting opens up possibilities for personalized drug testing, where printed organ models are used to simulate reactions and side effects in vitro, paving the way for safer and more effective treatments. Yet, the ethical, legal, and technical challenges remain steep. Regulatory approval, quality control, and questions of access and affordability dominate the conversation. Will life-saving organ printing become a tool for all or a luxury for the few? As we stand on the brink of biofabrication becoming mainstream, we must navigate not only the science but the societal frameworks that will define how this power is distributed.